A systematic review of the international prevalence of BRCA mutation in breast cancer
A systematic review was conducted, summarizing international or ( ) mutation prevalence in breast cancer. Databases (eg, Medline and Embase; N=7) and conferences were searched (January 2012 to December 2017). From 17,872 records, 70 studies were included. In 58 large (N>100) studies, mutation pre...
Saved in:
| Published in | Clinical epidemiology Vol. 11; pp. 543 - 561 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New Zealand
Dove Medical Press Limited
01.07.2019
Dove Dove Medical Press |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | A systematic review was conducted, summarizing international
or
(
) mutation prevalence in breast cancer. Databases (eg, Medline and Embase; N=7) and conferences were searched (January 2012 to December 2017). From 17,872 records, 70 studies were included. In 58 large (N>100) studies,
mutation prevalence varied widely from 1.8% (Spain) in sporadic breast cancer to 36.9% (United States) in estrogen receptor/progesterone receptor low+ (1-9% on immunohistochemistry/human epidermal growth factor receptor 2-negative [HER2-]) breast cancer. In 2 large studies unselected for family history, ethnicity, sex, or age and no/unclear selection by breast cancer stage or hormone receptor (HR) status, germline
(g
) mutation prevalence was 2.9% (Italy) to 3.0% (South Korea). In the 4 large unselected triple-negative breast cancer studies, g
mutation prevalence varied from 9.3% (Australia) to 15.4% (United States). g
mutation prevalence in 1 large unselected HR positive/HER2- early breast cancer study was 5% (United States). In 2 large unselected metastatic breast cancer studies, g
mutation prevalence was 2.7% (France) and 4.3% (Germany). Locally advanced breast cancer studies were small and not in unselected populations. Poor reporting of g
status and basis of selection implies a need for further large well-reported
mutation prevalence studies in breast cancer. |
|---|---|
| AbstractList | A systematic review was conducted, summarizing international BRCA 1 or 2 (BRCA1/2) mutation prevalence in breast cancer. Databases (eg, Medline and Embase; N=7) and conferences were searched (January 2012 to December 2017). From 17,872 records, 70 studies were included. In 58 large (N>100) studies, BRCA1/2 mutation prevalence varied widely from 1.8% (Spain) in sporadic breast cancer to 36.9% (United States) in estrogen receptor/progesterone receptor low+ (1-9% on immunohistochemistry/human epidermal growth factor receptor 2-negative [HER2-]) breast cancer. In 2 large studies unselected for family history, ethnicity, sex, or age and no/unclear selection by breast cancer stage or hormone receptor (HR) status, germline BRCA (gBRCA) mutation prevalence was 2.9% (Italy) to 3.0% (South Korea). In the 4 large unselected triple-negative breast cancer studies, gBRCA mutation prevalence varied from 9.3% (Australia) to 15.4% (United States). gBRCA mutation prevalence in 1 large unselected HR positive/HER2- early breast cancer study was 5% (United States). In 2 large unselected metastatic breast cancer studies, gBRCA mutation prevalence was 2.7% (France) and 4.3% (Germany). Locally advanced breast cancer studies were small and not in unselected populations. Poor reporting of gBRCA status and basis of selection implies a need for further large well-reported BRCA mutation prevalence studies in breast cancer. Keywords: BRCA1, BRCA2, prevalence, systematic review, chemotherapy A systematic review was conducted, summarizing international BRCA 1 or 2 (BRCA1/2) mutation prevalence in breast cancer. Databases (eg, Medline and Embase; N=7) and conferences were searched (January 2012 to December 2017). From 17,872 records, 70 studies were included. In 58 large (N>100) studies, BRCA1/2 mutation prevalence varied widely from 1.8% (Spain) in sporadic breast cancer to 36.9% (United States) in estrogen receptor/progesterone receptor low+ (1-9% on immunohistochemistry/human epidermal growth factor receptor 2-negative [HER2-]) breast cancer. In 2 large studies unselected for family history, ethnicity, sex, or age and no/unclear selection by breast cancer stage or hormone receptor (HR) status, germline BRCA (gBRCA) mutation prevalence was 2.9% (Italy) to 3.0% (South Korea). In the 4 large unselected triple-negative breast cancer studies, gBRCA mutation prevalence varied from 9.3% (Australia) to 15.4% (United States). gBRCA mutation prevalence in 1 large unselected HR positive/HER2- early breast cancer study was 5% (United States). In 2 large unselected metastatic breast cancer studies, gBRCA mutation prevalence was 2.7% (France) and 4.3% (Germany). Locally advanced breast cancer studies were small and not in unselected populations. Poor reporting of gBRCA status and basis of selection implies a need for further large well-reported BRCA mutation prevalence studies in breast cancer.A systematic review was conducted, summarizing international BRCA 1 or 2 (BRCA1/2) mutation prevalence in breast cancer. Databases (eg, Medline and Embase; N=7) and conferences were searched (January 2012 to December 2017). From 17,872 records, 70 studies were included. In 58 large (N>100) studies, BRCA1/2 mutation prevalence varied widely from 1.8% (Spain) in sporadic breast cancer to 36.9% (United States) in estrogen receptor/progesterone receptor low+ (1-9% on immunohistochemistry/human epidermal growth factor receptor 2-negative [HER2-]) breast cancer. In 2 large studies unselected for family history, ethnicity, sex, or age and no/unclear selection by breast cancer stage or hormone receptor (HR) status, germline BRCA (gBRCA) mutation prevalence was 2.9% (Italy) to 3.0% (South Korea). In the 4 large unselected triple-negative breast cancer studies, gBRCA mutation prevalence varied from 9.3% (Australia) to 15.4% (United States). gBRCA mutation prevalence in 1 large unselected HR positive/HER2- early breast cancer study was 5% (United States). In 2 large unselected metastatic breast cancer studies, gBRCA mutation prevalence was 2.7% (France) and 4.3% (Germany). Locally advanced breast cancer studies were small and not in unselected populations. Poor reporting of gBRCA status and basis of selection implies a need for further large well-reported BRCA mutation prevalence studies in breast cancer. A systematic review was conducted, summarizing international BRCA 1 or 2 ( BRCA1/2 ) mutation prevalence in breast cancer. Databases (eg, Medline and Embase; N=7) and conferences were searched (January 2012 to December 2017). From 17,872 records, 70 studies were included. In 58 large (N>100) studies, BRCA1/2 mutation prevalence varied widely from 1.8% (Spain) in sporadic breast cancer to 36.9% (United States) in estrogen receptor/progesterone receptor low+ (1–9% on immunohistochemistry/human epidermal growth factor receptor 2–negative [HER2-]) breast cancer. In 2 large studies unselected for family history, ethnicity, sex, or age and no/unclear selection by breast cancer stage or hormone receptor (HR) status, germline BRCA (g BRCA ) mutation prevalence was 2.9% (Italy) to 3.0% (South Korea). In the 4 large unselected triple-negative breast cancer studies, g BRCA mutation prevalence varied from 9.3% (Australia) to 15.4% (United States). g BRCA mutation prevalence in 1 large unselected HR positive/HER2- early breast cancer study was 5% (United States). In 2 large unselected metastatic breast cancer studies, g BRCA mutation prevalence was 2.7% (France) and 4.3% (Germany). Locally advanced breast cancer studies were small and not in unselected populations. Poor reporting of g BRCA status and basis of selection implies a need for further large well-reported BRCA mutation prevalence studies in breast cancer. A systematic review was conducted, summarizing international BRCA 1 or 2 (BRCA1/2) mutation prevalence in breast cancer. Databases (eg, Medline and Embase; N=7) and conferences were searched (January 2012 to December 2017). From 17,872 records, 70 studies were included. In 58 large (N>100) studies, BRCA1/2 mutation prevalence varied widely from 1.8% (Spain) in sporadic breast cancer to 36.9% (United States) in estrogen receptor/progesterone receptor low+ (1-9% on immunohistochemistry/human epidermal growth factor receptor 2-negative [HER2-]) breast cancer. In 2 large studies unselected for family history, ethnicity, sex, or age and no/unclear selection by breast cancer stage or hormone receptor (HR) status, germline BRCA (gBRCA) mutation prevalence was 2.9% (Italy) to 3.0% (South Korea). In the 4 large unselected triple-negative breast cancer studies, gBRCA mutation prevalence varied from 9.3% (Australia) to 15.4% (United States). gBRCA mutation prevalence in 1 large unselected HR positive/HER2- early breast cancer study was 5% (United States). In 2 large unselected metastatic breast cancer studies, gBRCA mutation prevalence was 2.7% (France) and 4.3% (Germany). Locally advanced breast cancer studies were small and not in unselected populations. Poor reporting of gBRCA status and basis of selection implies a need for further large well-reported BRCA mutation prevalence studies in breast cancer. Nigel Armstrong,1 Steve Ryder,1 Carol Forbes,2 Janine Ross,3 Ruben GW Quek41Health Economics, Kleijnen Systematic Reviews Ltd., York YO19 6FD, UK; 2Systematic Reviews, Kleijnen Systematic Reviews Ltd., York YO19 6FD, UK; 3Information, Kleijnen Systematic Reviews Ltd., York YO19 6FD, UK; 4Health Economics & Outcomes Research, Pfizer Inc., San Francisco, CA 94105, USAAbstract: A systematic review was conducted, summarizing international BRCA 1 or 2 (BRCA1/2) mutation prevalence in breast cancer. Databases (eg, Medline and Embase; N=7) and conferences were searched (January 2012 to December 2017). From 17,872 records, 70 studies were included. In 58 large (N>100) studies, BRCA1/2 mutation prevalence varied widely from 1.8% (Spain) in sporadic breast cancer to 36.9% (United States) in estrogen receptor/progesterone receptor low+ (1-9% on immunohistochemistry/human epidermal growth factor receptor 2-negative [HER2-]) breast cancer. In 2 large studies unselected for family history, ethnicity, sex, or age and no/unclear selection by breast cancer stage or hormone receptor (HR) status, germline BRCA (gBRCA) mutation prevalence was 2.9% (Italy) to 3.0% (South Korea). In the 4 large unselected triple-negative breast cancer studies, gBRCA mutation prevalence varied from 9.3% (Australia) to 15.4% (United States). gBRCA mutation prevalence in 1 large unselected HR positive/HER2- early breast cancer study was 5% (United States). In 2 large unselected metastatic breast cancer studies, gBRCA mutation prevalence was 2.7% (France) and 4.3% (Germany). Locally advanced breast cancer studies were small and not in unselected populations. Poor reporting of gBRCA status and basis of selection implies a need for further large well-reported BRCA mutation prevalence studies in breast cancer.Keywords: BRCA1, BRCA2, prevalence, systematic review, chemotherapy A systematic review was conducted, summarizing international or ( ) mutation prevalence in breast cancer. Databases (eg, Medline and Embase; N=7) and conferences were searched (January 2012 to December 2017). From 17,872 records, 70 studies were included. In 58 large (N>100) studies, mutation prevalence varied widely from 1.8% (Spain) in sporadic breast cancer to 36.9% (United States) in estrogen receptor/progesterone receptor low+ (1-9% on immunohistochemistry/human epidermal growth factor receptor 2-negative [HER2-]) breast cancer. In 2 large studies unselected for family history, ethnicity, sex, or age and no/unclear selection by breast cancer stage or hormone receptor (HR) status, germline (g ) mutation prevalence was 2.9% (Italy) to 3.0% (South Korea). In the 4 large unselected triple-negative breast cancer studies, g mutation prevalence varied from 9.3% (Australia) to 15.4% (United States). g mutation prevalence in 1 large unselected HR positive/HER2- early breast cancer study was 5% (United States). In 2 large unselected metastatic breast cancer studies, g mutation prevalence was 2.7% (France) and 4.3% (Germany). Locally advanced breast cancer studies were small and not in unselected populations. Poor reporting of g status and basis of selection implies a need for further large well-reported mutation prevalence studies in breast cancer. |
| Audience | Academic |
| Author | Quek, Ruben GW Ross, Janine Armstrong, Nigel Forbes, Carol Ryder, Steve |
| Author_xml | – sequence: 1 givenname: Nigel orcidid: 0000-0002-7443-4798 surname: Armstrong fullname: Armstrong, Nigel – sequence: 2 givenname: Steve orcidid: 0000-0003-1177-416X surname: Ryder fullname: Ryder, Steve – sequence: 3 givenname: Carol orcidid: 0000-0001-6273-8455 surname: Forbes fullname: Forbes, Carol – sequence: 4 givenname: Janine orcidid: 0000-0002-4763-2078 surname: Ross fullname: Ross, Janine – sequence: 5 givenname: Ruben GW orcidid: 0000-0001-9602-3239 surname: Quek fullname: Quek, Ruben GW |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31372057$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkt1r2zAUxc3oWLuub3sehsHYw5Lpy5L8MshCtxUCG9v6LGT5OlGxpVRSOvrfT67TkYzaYBmd3z3cK52XxYnzDoriNUZzgpn4uFxd_pj_IojXrH5WnGEs6hmmrD45-D8tLmK8QfmhFAuBXhSnFFNBUCXOiutFGe9jgkEna8oAdxb-lL4r0wZK6xIElwXvdF9us6h7cAZG_fPP5aIcdulBzWTZBNAxlUZnILwqnne6j3CxX8-L6y-Xv5ffZqvvX6-Wi9XMcMzSjApDqaikrIkhWmDQTdPlPiUyYFhVy6ZquW4o1IQ1nRGYN1XVoo6ziuRvR8-Lq8m39fpGbYMddLhXXlv1sOHDWumQB-tBceCd5JRJ1CDGqNQyH0BbAyWt1LqR2evT5LXdNQO0BlwKuj8yPVac3ai1v1OcE1kzkQ3e7w2Cv91BTGqw0UDfawd-FxUhXFLEK44z-nZC1_lElXWdz45mxNWCI1wjydHY0fwJKr8tDNbkIHQ27x8VvDso2IDu0yb6fjfeUTwG3xzO-m_Ix1xkgEyACT7GAJ0ydrrr3ILtFUZqzJ8a86f2-ctFH_4revR9Ev8LgnjYlA |
| CitedBy_id | crossref_primary_10_1080_21548331_2023_2266019 crossref_primary_10_1371_journal_pone_0306612 crossref_primary_10_1007_s00439_020_02126_6 crossref_primary_10_1245_s10434_022_11347_0 crossref_primary_10_1016_j_esmoop_2023_101207 crossref_primary_10_1093_nar_gkac948 crossref_primary_10_1159_000538021 crossref_primary_10_1200_PO_22_00309 crossref_primary_10_1038_s41571_020_0388_9 crossref_primary_10_3390_cancers17010039 crossref_primary_10_1016_j_heliyon_2023_e23383 crossref_primary_10_1016_j_clon_2024_08_006 crossref_primary_10_26442_20795696_2023_3_202360 crossref_primary_10_3390_ijms24054741 crossref_primary_10_1016_j_jddst_2024_105401 crossref_primary_10_1515_chem_2024_0064 crossref_primary_10_4274_ejbh_galenos_2023_2023_2_5 crossref_primary_10_1002_1878_0261_13024 crossref_primary_10_1007_s00404_022_06819_3 crossref_primary_10_3390_ijms22031266 crossref_primary_10_1111_cas_14986 crossref_primary_10_1002_ijc_34304 crossref_primary_10_1159_000513596 crossref_primary_10_1016_j_ajcnut_2022_11_019 crossref_primary_10_4264_numa_83_4_131 crossref_primary_10_1016_j_ygyno_2024_01_016 crossref_primary_10_1016_j_currproblcancer_2021_100767 crossref_primary_10_3390_cancers17010145 crossref_primary_10_1007_s10549_024_07503_7 crossref_primary_10_5501_wjv_v10_i5_229 crossref_primary_10_1016_j_lanepe_2024_100886 crossref_primary_10_1080_09513590_2021_2002294 crossref_primary_10_1007_s10549_023_07102_y crossref_primary_10_1111_jog_14952 crossref_primary_10_1007_s11306_023_02024_8 crossref_primary_10_1016_j_ijbiomac_2020_09_230 crossref_primary_10_3389_fcell_2020_564601 crossref_primary_10_1371_journal_pone_0291015 crossref_primary_10_1007_s11912_022_01339_4 crossref_primary_10_1200_OA_24_00079 crossref_primary_10_2147_BCTT_S303047 crossref_primary_10_1007_s00394_024_03379_x crossref_primary_10_1007_s10549_025_07651_4 crossref_primary_10_3390_jpm12101740 crossref_primary_10_1038_s41523_021_00279_9 crossref_primary_10_3390_cancers14112804 crossref_primary_10_3233_BD_220002 crossref_primary_10_1245_s10434_021_10870_w crossref_primary_10_1016_j_ins_2024_121033 crossref_primary_10_1016_j_ejca_2021_03_029 crossref_primary_10_1038_s41416_024_02607_9 crossref_primary_10_1136_gutjnl_2021_326522 crossref_primary_10_1186_s12935_021_02194_2 crossref_primary_10_1001_jamanetworkopen_2024_61639 crossref_primary_10_1177_1178223421996279 crossref_primary_10_18553_jmcp_2024_30_9_942 crossref_primary_10_1080_14737167_2023_2169135 crossref_primary_10_1016_j_mayocpiqo_2023_08_006 crossref_primary_10_1038_s41416_022_02003_1 crossref_primary_10_1002_ijc_34687 crossref_primary_10_1177_09622802211047346 crossref_primary_10_2478_bjmg_2020_0016 crossref_primary_10_1007_s10549_022_06692_3 crossref_primary_10_1016_j_gimo_2023_100849 crossref_primary_10_1080_17512433_2020_1839416 crossref_primary_10_1097_PGP_0000000000001055 crossref_primary_10_1200_GO_21_00051 crossref_primary_10_3390_cells9040941 crossref_primary_10_1200_PO_24_00026 crossref_primary_10_1038_s41416_024_02827_z crossref_primary_10_1007_s10549_022_06572_w crossref_primary_10_5306_wjco_v15_i7_848 crossref_primary_10_3390_ijerph192315785 crossref_primary_10_2340_1651_226X_2024_40829 crossref_primary_10_3390_genes15121616 crossref_primary_10_1016_j_clbc_2020_12_011 crossref_primary_10_3390_genes14010106 crossref_primary_10_5306_wjco_v15_i12_1481 crossref_primary_10_1136_bmjopen_2019_031727 crossref_primary_10_3390_app11219800 crossref_primary_10_3390_cancers17030400 crossref_primary_10_32074_1591_951X_123 crossref_primary_10_1016_j_breast_2021_12_005 crossref_primary_10_2147_IJGM_S355755 crossref_primary_10_1016_j_clbc_2023_04_006 crossref_primary_10_3390_ijms242317086 crossref_primary_10_1007_s00761_020_00729_2 crossref_primary_10_1111_vco_12685 crossref_primary_10_26508_lsa_202201673 crossref_primary_10_1007_s10555_021_10013_3 crossref_primary_10_3390_cancers12102957 crossref_primary_10_3390_cancers13143535 crossref_primary_10_7554_eLife_78163 crossref_primary_10_1002_cnr2_1664 crossref_primary_10_1111_jcmm_17465 crossref_primary_10_3390_nu16162644 crossref_primary_10_1136_jmg_2023_109185 crossref_primary_10_1007_s12192_021_01214_4 crossref_primary_10_18027_2224_5057_2021_11_2_38_44 crossref_primary_10_1016_j_pharmthera_2021_108009 crossref_primary_10_3390_jcm12041422 crossref_primary_10_1007_s11033_021_06499_3 crossref_primary_10_1007_s11523_021_00796_4 crossref_primary_10_1186_s40543_023_00400_6 crossref_primary_10_1038_s41416_021_01514_7 crossref_primary_10_1007_s12032_023_02074_x crossref_primary_10_1016_j_bbcan_2023_188907 crossref_primary_10_3390_curroncol29070368 crossref_primary_10_1038_s10038_020_00849_y crossref_primary_10_1093_carcin_bgad071 crossref_primary_10_1038_s41467_020_17458_0 crossref_primary_10_1007_s43032_024_01666_w crossref_primary_10_3390_cancers15153847 crossref_primary_10_1146_annurev_genom_083118_015253 crossref_primary_10_3390_genes12040519 crossref_primary_10_1016_j_mtbio_2025_101497 crossref_primary_10_1186_s13053_021_00176_z crossref_primary_10_1007_s40487_023_00240_9 crossref_primary_10_1007_s12609_020_00370_3 crossref_primary_10_1186_s12885_022_09943_0 crossref_primary_10_1038_s41416_022_02111_y crossref_primary_10_3390_cancers13092262 crossref_primary_10_1016_j_breast_2021_09_008 crossref_primary_10_3390_diagnostics14171875 crossref_primary_10_26565_2313_6693_2021_42_08 crossref_primary_10_3389_fmed_2022_863468 crossref_primary_10_1002_ijc_34525 crossref_primary_10_2217_fon_2021_1387 crossref_primary_10_3389_fonc_2023_1125021 crossref_primary_10_1016_j_isci_2024_110180 crossref_primary_10_1097_MD_0000000000017114 crossref_primary_10_1016_j_clbc_2023_05_012 crossref_primary_10_1016_j_clbc_2023_05_014 crossref_primary_10_1016_j_meegid_2021_105086 crossref_primary_10_1002_INMD_20220013 crossref_primary_10_1007_s10549_020_05611_8 crossref_primary_10_1016_j_ejca_2022_10_021 crossref_primary_10_1088_1361_6498_acd857 crossref_primary_10_1016_j_lfs_2023_121790 crossref_primary_10_3390_cimb45080418 crossref_primary_10_3892_ijmm_2024_5388 crossref_primary_10_1007_s00292_021_00929_6 crossref_primary_10_1186_s12885_021_09074_y crossref_primary_10_7717_peerj_8403 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2019 Dove Medical Press Limited 2019 Armstrong et al. 2019 Armstrong et al. |
| Copyright_xml | – notice: COPYRIGHT 2019 Dove Medical Press Limited – notice: 2019 Armstrong et al. 2019 Armstrong et al. |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.2147/CLEP.S206949 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals(OpenAccess) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Public Health |
| DocumentTitleAlternate | Armstrong et al |
| EISSN | 1179-1349 |
| EndPage | 561 |
| ExternalDocumentID | oai_doaj_org_article_6e6f863480b04438a8205d9e32d8aab8 PMC6628947 A601908608 31372057 10_2147_CLEP_S206949 |
| Genre | Journal Article Review |
| GeographicLocations | South Korea United States Texas United Kingdom Australia Germany Spain |
| GeographicLocations_xml | – name: United Kingdom – name: Germany – name: South Korea – name: Australia – name: Spain – name: United States – name: Texas |
| GroupedDBID | --- 0YH 29B 2WC 53G 5VS 8C1 8G5 AAYXX ABUWG ADBBV ADRAZ AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BPHCQ C1A CCPQU CITATION DIK DWQXO E3Z EBD FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HYE IAO IHR IHW IPNFZ ITC KQ8 M2O M48 M~E O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RIG RPM TDBHL TR2 UKHRP VDV NPM PMFND 7X8 PPXIY 5PM PJZUB PUEGO |
| ID | FETCH-LOGICAL-c614t-37c33758892c2a71eabbf00080cec4598b5d6ab3e924bfc716b55d0f64520f6f3 |
| IEDL.DBID | DOA |
| ISSN | 1179-1349 |
| IngestDate | Wed Aug 27 01:29:12 EDT 2025 Thu Aug 21 18:18:22 EDT 2025 Thu Jul 10 22:35:32 EDT 2025 Tue Jun 17 21:09:22 EDT 2025 Tue Jun 10 20:12:12 EDT 2025 Thu May 22 21:22:11 EDT 2025 Mon Mar 03 18:06:51 EST 2025 Tue Jul 01 02:28:41 EDT 2025 Thu Apr 24 22:58:03 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | prevalence BRCA1 BRCA2 systematic review chemotherapy |
| Language | English |
| License | http://creativecommons.org/licenses/by-nc/3.0 This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c614t-37c33758892c2a71eabbf00080cec4598b5d6ab3e924bfc716b55d0f64520f6f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0003-1177-416X 0000-0002-7443-4798 0000-0002-4763-2078 0000-0001-9602-3239 0000-0001-6273-8455 |
| OpenAccessLink | https://doaj.org/article/6e6f863480b04438a8205d9e32d8aab8 |
| PMID | 31372057 |
| PQID | 2268306561 |
| PQPubID | 23479 |
| PageCount | 19 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_6e6f863480b04438a8205d9e32d8aab8 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6628947 proquest_miscellaneous_2268306561 gale_infotracmisc_A601908608 gale_infotracacademiconefile_A601908608 gale_healthsolutions_A601908608 pubmed_primary_31372057 crossref_citationtrail_10_2147_CLEP_S206949 crossref_primary_10_2147_CLEP_S206949 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-07 |
| PublicationDateYYYYMMDD | 2019-07-01 |
| PublicationDate_xml | – month: 07 year: 2019 text: 2019-07 |
| PublicationDecade | 2010 |
| PublicationPlace | New Zealand |
| PublicationPlace_xml | – name: New Zealand |
| PublicationTitle | Clinical epidemiology |
| PublicationTitleAlternate | Clin Epidemiol |
| PublicationYear | 2019 |
| Publisher | Dove Medical Press Limited Dove Dove Medical Press |
| Publisher_xml | – name: Dove Medical Press Limited – name: Dove – name: Dove Medical Press |
| SSID | ssj0000331770 |
| Score | 2.5565562 |
| SecondaryResourceType | review_article |
| Snippet | A systematic review was conducted, summarizing international
or
(
) mutation prevalence in breast cancer. Databases (eg, Medline and Embase; N=7) and... A systematic review was conducted, summarizing international BRCA 1 or 2 (BRCA1/2) mutation prevalence in breast cancer. Databases (eg, Medline and Embase;... A systematic review was conducted, summarizing international BRCA 1 or 2 ( BRCA1/2 ) mutation prevalence in breast cancer. Databases (eg, Medline and Embase;... Nigel Armstrong,1 Steve Ryder,1 Carol Forbes,2 Janine Ross,3 Ruben GW Quek41Health Economics, Kleijnen Systematic Reviews Ltd., York YO19 6FD, UK; 2Systematic... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 543 |
| SubjectTerms | BRCA1 BRCA2 Breast cancer Cancer metastasis Cancer research Chemotherapy Conferences and conventions Epidermal growth factors Estrogens Genetic aspects Hormones Olaparib Pharmaceutical industry Phenols (Class of compounds) prevalence Review systematic review |
| Title | A systematic review of the international prevalence of BRCA mutation in breast cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31372057 https://www.proquest.com/docview/2268306561 https://pubmed.ncbi.nlm.nih.gov/PMC6628947 https://doaj.org/article/6e6f863480b04438a8205d9e32d8aab8 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELdgvCAhxDcZoxgJxAMKS-OP2I9t1alCME2DSuPJsh1bmwRp1bX__-7irCRCiBde8hCfkvh857tz7n5HyLtoGY-1srnTzuVc8yJXWgoIVYSP0QpW1FiN_PVULpb884W46LX6wpywBA-cGHcsg4xKMq4KV3DOlAWTJWodWAlvsK4t8wWb1wum2j2YgV1sO8Uh5FmOGHwp6x3b8hzDc9efrkus-dQDe9TC9v-5Ofes0zBzsmeKTh6Rh50PSSfp2x-TO6F5Qh6kAzia6oqekuWE_kZppqlCha4iBYePXvWPAel6g5DfqOE4Pj2fTeivXfpDD5TUYdr6lnoUj80zsjyZf58t8q6HQu7B8G5h__CMQUygdOlLW42DdS62fqIPngutnKildSxAHOaih-jJCVEXEf93wjWy5-SgWTXhJaEKlrtktdO8tFzbEgKlUIHJj3gwJZXPyMdbThrfAYxjn4ufBgIN5LuZfZmfmW-J7xl5v6deJ2CNv9BNcVH2NAiH3d4AITGdkJh_CUlG3uCSmlRbuldqM5FYSq9kARQfWgpUa_hob7vqBJg6AmQNKI8GlKCOfjD89lZsDA5hDlsTVrtrA46uggANHNaMvEhitJ8VG2O3IFFlpBoI2GDaw5Hm6rJFA5cSYmZeHf4PPr0i98Eh1Ckd-YgcbDe78Bqcrq0bkbvFjwVc1Ww8Ivem89Oz81GrczevKCoC |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+systematic+review+of+the+international+prevalence+of+BRCA+mutation+in+breast+cancer&rft.jtitle=Clinical+epidemiology&rft.au=Armstrong%2C+Nigel&rft.au=Ross%2C+Janine&rft.au=Ryder%2C+Steve&rft.au=Quek%2C+Ruben+G.W&rft.date=2019-07-01&rft.pub=Dove+Medical+Press+Limited&rft.issn=1179-1349&rft.eissn=1179-1349&rft.spage=543&rft_id=info:doi/10.2147%2Fclep.s206949&rft.externalDBID=n%2Fa&rft.externalDocID=A601908608 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1179-1349&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1179-1349&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1179-1349&client=summon |